| Literature DB >> 27487016 |
Alexander Akleyev1,2, Isabelle Deltour3, Lyudmila Krestinina1, Mikhail Sokolnikov4, Yulia Tsareva4, Evgenia Tolstykh1, Joachim Schüz3.
Abstract
BACKGROUND: Previous studies have shown that acute external in utero exposure to ionizing radiation can increase cancer risk. It is not known whether chronic exposure at low dose rates, including due to radionuclide intake, influences the lifetime risk of solid cancers in the offspring. The objective of this study was to investigate solid cancer risk after in utero irradiation.Entities:
Mesh:
Year: 2016 PMID: 27487016 PMCID: PMC4972315 DOI: 10.1371/journal.pone.0160372
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characterization of the status at the end of the follow up of the Urals Prenatally Exposed Cohort:, sex, birth year, ethnicity, and dose.
| Characteristic | Number (%) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mortality | Incidence | |||||||||||||||
| No. observed | Alive | Died from solid cancer | Died from other causes | Lost to follow-up | Person-years | No. observed | Alive | Died | Solid cancer diagnosis | Lost to follow-up | Person-years | |||||
| Status unknown | Migrants | Other cancer cases | Status unknown | Migrants | ||||||||||||
| 16,821 (100) | 7,954 (47.3) | 196 (1.2) | 2903 (17.3) | 1,230 (7.3) | 4,538 (27.0) | 601,372 | 15,813 (100) | 7,093 (44.9) | 2,130 (13.5) | 369 (2.3) | 56 (0.4) | 885 (5.6) | 5,280 (33.4) | 554,411 | ||
| Sex | Male | 8,552 (50.8) | 3,597 | 115 | 1,970 | 653 | 2217 | 300,159 | 8,024 (50.7) | 3,262 | 1,521 | 175 | 31 | 482 | 2,553 | 278,324 |
| Female | 8,269 (49.2) | 4,357 | 81 | 933 | 577 | 2321 | 301,213 | 7,789 (49.3) | 3,831 | 609 | 194 | 25 | 403 | 2,727 | 276,087 | |
| Birth year | 1950–1953 | 5,704 (33.9) | 2,244 | 92 | 1,239 | 316 | 1813 | 195,336 | 4,998 (31.6) | 1,996 | 680 | 168 | 19 | 154 | 1,981 | 174,059 |
| 1954–1957 | 6,106 (36.3) | 2,916 | 69 | 1,022 | 480 | 1619 | 221,090 | 5,860 (37.1) | 2,569 | 836 | 128 | 25 | 360 | 1,942 | 205,566 | |
| 1958–1961 | 5,011 (29.8) | 2,794 | 35 | 642 | 434 | 1106 | 184,946 | 4,955 (31.3) | 2,528 | 614 | 73 | 12 | 372 | 1,356 | 174,786 | |
| Ethnicity/place of residence | Slavs | 7,607 (45.2) | 3,503 | 92 | 1,355 | 780 | 1877 | 273,442 | 6,907 (43.7) | 2,899 | 860 | 158 | 19 | 527 | 2,444 | 236,578 |
| Tatars and Bashkirs | 3,883 (23.1) | 2,266 | 38 | 874 | 347 | 358 | 154,537 | 3,575 (22.6) | 2,081 | 626 | 80 | 7 | 255 | 526 | 145,371 | |
| Subset of MWOC | 5,331 (31.7) | 2,185 | 66 | 674 | 103 | 2303 | 173,393 | 5,331 (33.7) | 2,113 | 644 | 131 | 30 | 103 | 2,310 | 172,462 | |
| Dose | < 1 mGy | 9969 (59.3) | 4888 (61.5) | 105 (53.6) | 1579 (54.4) | 817 (66.4) | 2580 (56.9) | 362488 | 9592 (60.7) | 4358 | 1301 | 195 | 31 | 644 | 1062 | 336538 |
| 1–4 mGy | 2580 (15.3) | 1316 (16.5) | 36 (18.4) | 537 (18.5) | 179 (14.6) | 512 (11.3) | 97706.9 | 2323 (14.7) | 1150 | 332 | 71 | 3 | 115 | 652 | 87921.9 | |
| 5–19 mGy | 2054 (12.2) | 931 (11.7) | 29 (14.8) | 427 (14.7) | 146 (11.9) | 521 (11.5) | 73323 | 1809 (11.4) | 828 | 244 | 56 | 7 | 75 | 599 | 66064.6 | |
| 20–79 mGy | 1418 (8.4) | 564 (7.1) | 19 (9.7) | 251 (8.6) | 68 (5.5) | 516 (11.4) | 45950.9 | 1304 (8.2) | 518 | 159 | 33 | 10 | 36 | 548 | 42674.9 | |
| 80+ mGy | 800 (4.8) | 255 (3.2) | 7 (3.6) | 109 (3.8) | 20 (1.6) | 409 (9.0) | 21903.4 | 785 (5.0) | 239 | 94 | 14 | 5 | 15 | 418 | 21166.8 | |
*ICD-9 Codes 140–199 excluding 173
**Other cancers: hematological malignancies (ICD-9 Codes 200–208), non-melanoma skin cancers (ICD-9 Code 173) and unspecified tumours (ICD-9 Code 239)
Characteristics of dose distributions for the mortality analysis of the Techa River in Utero Exposed Cohort (TRCIU; n = 11,490), the Mayak Female Workers’ Offspring Cohort exposed in utero (MWOC; n = 5,331), and Urals Prenatally Exposed Cohort (UPEC, n = 16,821).
| Cohort | Period of exposure | Absorbed dose, mGy | ||||
|---|---|---|---|---|---|---|
| Mean | 25th percentile | Median | 75th percentile | Maximum | ||
| TRCIU | In utero | 4.4 | 0.04 | 0.3 | 2.2 | 294.5 |
| Postnatal | 10.4 | 0.1 | 1.3 | 8.6 | 397.1 | |
| MWOC | In utero | 35.0 | 0* | 0 | 30.4 | 944.9 |
| Postnatal | 12.8 | 0 | 0 | 0 | 552.0 | |
| UPEC | In utero | 14.1 | 0 | 0.3 | 5.2 | 944.9 |
| Postnatal | 11.2 | 0 | 0.4 | 5.3 | 552.0 | |
Distribution of incident cancer cases in the UPEC.
| Men | Women | |||||
|---|---|---|---|---|---|---|
| Site (ICD-9 Code) | N | % | Mean age(Range) | N | % | Mean age(Range) |
| DigestiveOesophagus (150)Stomach (151)Colorectal (153–154)Liver (155)Other digestive (152,156–159) | 4921816211 | 45(1–58)48 (47–49)45(29–56)47(34–58)41(40–42)41(1–58) | 430142126 | 47(11–59)-48(40–58)47(25–5929 (11–47)47(37–56) | ||
| RespiratoryLung (162)Other respiratory (160, 161, 163–165) | 584810 | 48(27–59)49(27–59)46(29–54) | 651 | 43(37–51)44(37–51)40 | ||
| Breast (174–175) | 0 | 49 | 47(31–58) | |||
| Other sites (same as last line?)Cervix (180)Prostate (185)Bladder (188)Brain/CNS (191–192)Thyroid (193)Other (within 140–199) | -0211649 | 35(29–41)31(8–52)39(33–44)41(1–57) | 20-061951 | 41 (27–56)—42(29–50)43(24–54)41(1–58) |
Excluding non-melanoma skin cancer (173).
Relative risks for solid cancer incidence and mortality with mutual adjustment for in utero and postnatal exposure to radiation in the Urals Prenatally Exposed Cohort.
| Dose | Incidence | Mortality | ||||
|---|---|---|---|---|---|---|
| Person-years | No. observed | RR (95% CI) | Person-years | No. observed | RR (95% CI) | |
| < 1 | 336,583 | 195 | (Referent) | 362,488 | 105 | (Referent) |
| 1–4 | 87,922 | 71 | 1.32 (0.97 to 1.77) | 97,707 | 36 | 1.21(0.79 to 1.82) |
| 5–19 | 66,065 | 56 | 1.19 (0.86 to 1.62) | 73,323 | 29 | 1.14 (0.72 to 1.74) |
| 20–79 | 42,675 | 33 | 0.97 (0.64 to 1.41) | 45,951 | 19 | 1.08 (0.63 to 1.78) |
| >80 | 21,167 | 14 | 0.72 (0.39 to 1.22) | 21,903 | 7 | 0.65 (0.26 to 1.37) |
| < 1 | 325,580 | 161 | (Referent) | 351,742 | 83 | (Referent) |
| 1–4 | 88,475 | 59 | 0.90 (0.64 to 1.27) | 98,329 | 36 | 0.98 (0.62 to 1.53) |
| 5–19 | 81,880 | 65 | 1.02 (0.73 to 1.43) | 88,428 | 33 | 0.92 (0.57 to 1.45) |
| 20–79 | 44,061 | 53 | 1.17 (0.82 to 1.66) | 47,355 | 28 | 1.07 (0.65 to 1.71) |
| >80 | 14,416 | 31 | 1.72 (1.12 to 2.57) | 15,519 | 17 | 1.56 (0.87 to 2.67) |
| Linear/10 mGy in utero | 554,411 | 369 | 0.98 (0.96 to 1.01) | 601,372 | 196 | 0.98 (0.94 to 1.01) |
| Linear/10 mGy postnatal | 554,411 | 369 | 1.02 (1.00 to 1.04) | 601,372 | 196 | 1.02 (0.99 to 1.05) |
*non-melanoma skin cancers excluded
Relative risks for cancer incidence in the digestive system, respiratory system, and breast (women only) with mutual adjustment of in utero and postnatal exposure in the Urals Prenatally Exposed Cohort.
| Dose | Digestive cancers (ICD-9 codes 150–159) | Respiratory cancers (ICD-9 codes 160–165) | Breast cancer (ICD-9 code 174) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Person-years | No. observed | RR (95% CI) | Person-years | No. observed | RR (95% CI) | Person-years | No. observed | RR (95% CI) | |
| < 1 | 336,583 | 42 | (Referent) | 336,583 | 29 | (Referent) | 165,838 | 32 | (Referent) |
| 1–4 | 87,922 | 17 | 1.38 (0.74 to 2.51) | 87,922 | 20 | 2.02 (1.07 to 3.76) | 45,920 | 10 | 1.16 (0.51 to 2.45) |
| 5–19 | 66,065 | 16 | 1.53 (0.80 to 2.78) | 66,065 | 10 | 1.26 (0.57 to 2.61) | 32,540 | 3 | 0.45 (0.11 to 1.31) |
| 20–79 | 42,675 | 13 | 1.72 (0.85 to 3.30) | 42,675 | 2 | 0.40 (0.06 to 1.39) | 21,489 | 3 | 0.76 (0.18 to 2.21) |
| >80 | 21,167 | 3 | 1.05 (0.31 to 2.72) | 21,167 | 3 | 1.38 (0.32 to 4.26) | 10,300 | 1 | 0.41 (0.02 to 1.96) |
| < 1 | 325,580 | 34 | (Referent) | 325,580 | 16 | (Referent) | 166,291 | 27 | (Referent) |
| 1–4 | 88,475 | 14 | 1.02 (0.51 to 1.94) | 88,475 | 15 | 1.40 (0.64 to 3.03) | 44,819 | 9 | 0.78 (0.33 to 1.65) |
| 5–19 | 81,880 | 15 | 0.97 (0.49 to 1.84) | 81,880 | 13 | 1.11 (0.49 to 2.48) | 40,576 | 8 | 0.73 (0.29 to 1.66) |
| 20–79 | 44,061 | 17 | 1.26 (0.65 to 2.37) | 44,061 | 12 | 1.63 (0.70 to 3.67) | 19,086 | 4 | 0.50 (0.14 to 1.36) |
| >80 | 14,416 | 11 | 2.29 (1.09 to 4.56) | 14,416 | 8 | 2.62 (1.02 to 6.26) | 5,315 | 1 | 0.29 (0.02 to 1.41) |
| Linear/10 mGy in utero | 554,411 | 92 | 1.01 (0.97 to 1.04) | 554,411 | 64 | 1.00 (0.92 to 1.05) | 276,087 | 49 | 0.90 (0.71 to 1.01) |
| Linear/10 mGy postnatal | 554,411 | 92 | 1.04 (1.00 to 1.07) | 554,411 | 64 | 1.03 (0.98 to 1.06) | 276,087 | 49 | 0.95 (0.82 to 1.03) |
* adjustment on sex, age, and ethnicity/place of residence
** adjustment on age (linear and quadratic terms), among women only
Relative risks for incidence of all solid cancers, cancers of the digestive system and of the breast (women only), in a subcohort truncated at the postnatal dose of 10 mGy.
| In utero dose, mGy | All solid cancers (ICD-9 codes 140–199, except code 173 –non-melanoma skin cancer) | Digestive cancers (ICD-9 codes 150–159) | Breast cancer (ICD-9 code 174) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Person-years | No. observed | RR (95% CI) | Person-years | No. observed | RR (95% CI) | Person-years | No. observed | RR (95% CI) | |
| < 1 | 303,271 | 150 | (Referent) | 303,271 | 28 | (Referent) | 152,733 | 25 | (Referent) |
| 1–4 | 60,573 | 40 | 1.39 (0.96 to 1.97) | 60,573 | 10 | 1.70 (0.78 to 3.46) | 31,935 | 8 | 1.45 (0.61 to 3.09) |
| 5–19 | 42,325 | 28 | 1.18 (0.77 to 1.73) | 42,325 | 7 | 1.54 (0.62 to 3.35) | 20,671 | 2 | 0.50 (0.08 to 1.70) |
| 20–79 | 24,143 | 13 | 0.89 (0.47 to 1.54) | 24,143 | 3 | 1.27 (0.29 to 3.93) | 12,666 | 2 | 0.90 (0.14 to 3.02) |
| >80 | 17,945 | 10 | 0.79 (0.38 to 1.47) | 17,945 | 4 | 1.95 (0.54 to 5.63) | 9,349 | 1 | 0.56 (0.03 to 2.65) |
| Linear/10 mGy | 448,256 | 241 | 0.98 (0.95 to 1.01) | 448,256 | 52 | 1.02 (0.97 to 1.06) | 227,354 | 38 | 0.94 (0.76 to 1.03) |
*adjusted for sex, age (linear and quadratic coefficient), and ethnicity/place of residence (Slavs, Tatars and Bashkirs, Ozyorsk residents)
**adjusted for age (linear and quadratic coefficient) among women only